Valopicitabine Combined with Standard of Care Cleared Hepatitis C
Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a
Phase II Trial
~
Valopicitabine achieved both primary and secondary endpoints ofstudy; no negative drug-drug interaction was observed between
valopicitabine and ribavirin ~ CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- IdenixPharmaceuticals, Inc. today announced results from a phase II studydesigned to evaluate triple combination therapy, consisting of
valopicitabine (NM283), Idenix's lead dru...
Idenix Reports Results from Two Phase IIb Studies of the
Combination of Valopicitabine and Pegylated Interferon in Hepatitis
C Genotype-1 Patients at the 42nd Annual Meeting of the European
Association for the Study of the Liver
Additional Preclinical Data Presented on
Valopicitabine Combinedwith an Investigational Protease Inhibitor BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ --Idenix Pharmaceuticals, Inc. today announced results from two phaseIIb studies of the novel combination of
valopicitabine (NM283) andpegylated interferon alfa-2a (Pegasys(R)) in both treatment-naiveand treatment- experienced p...